Dr. Arpeet Shah discusses refining prostate cancer risk stratification.

Dr. Arpeet Shah Urology Times

Dr. Arpeet Shah recently participated in a two-part discussion October 14, 2025 with Dr. Jason Hafron, CMO of Michigan Institute of Urology and cochair of the Solaris clinical board.  This was a deep dive into how structure-based biomarkers like IsoPSA are refining prostate cancer risk stratification. In this discussion hosted by Urology Times, Dr. Arpeet…

Read More